Advertisement
Advertisement

Cobicistat Compared to Ritonavir to Boost Atazanavir in Treatment-Naive Patients

May/June 2013

Results from a recent randomized, double-blind, double placebo, phase III study comparing cobicistat to ritonavir to boost atazanavir were published in the 26 March edition of the Journal of Infectious Diseases.1

Cobicistat is an inhibitor of cytochrome P450 3A4 is currently approved as one component of the four-in-one fixed dose combination Stribild, where it boosts the integrase inhibitor elvitegravir.

It is a weak inhibitor of CYP2D6 but not other CYP or UGT pathways and has a similar effect to ritonavir on other drug transporters including P-gp, BCRP, and OATP1B1/3. Unlike ritonavir, cobicistat has no activity against HIV, but it is not always interchangeable with ritonavir (for example, it can't be used to boost tipranavir).

Advertisement
The study included 692 treatment-naive patients, and reported that cobicistat was non-inferior to ritonavir as a booster for atazanavir based on viral efficacy <50 copies/mL at 48 weeks.

Although the side effect profile appears to offer few advantages compared to ritonavir, cobicistat is being coformulated with both atazanavir and darunavir to simplify dosing. These studies provide a clearer data set for the efficacy and safety of cobicistat compared to ritonavir, as use in Stribild is complicated by the impact of elvitegravir.

Mean (+/-SD) baseline characteristics included: age 37 years (+/-9.8), CD4 350 (+/- 170) cells/mm3 (17% <200 and 14% >500) with median viral load 4.8 log copies/mL. Approximately 17% were women with 60% white, 18% black and 28% Hispanic. As with studies as part of Stribild, baseline entry criteria included no prior renal disease, defined as eGFR levels >70 mL/min.

Tenofovir DF/FTC was used as a background NRTIs for all patients. Response rates were 85% vs 87% (difference -2.2%; 95% CI -7.4% to +3.0%, p=0.40) in the cobicistat vs ritonavir groups respectively, using FDA ITT snapshot analysis, with no difference for the approximately 40% of patients with viral load >100,000 copies/mL at baseline (86% suppressed in each arm).

Side effects were generally mild and broadly comparable, accounting for 7% of patients discontinuing in each arm. The most commonly reported side effects (in >10% patients) included jaundice (21% vs 16%), scleral icterus (yellow eyes, 18% each arm), nausea (~17%), diarrhea (15% vs 20%), headache (11% vs 15%) and hyperbilirubinemia (11% vs 100%); all cobicistat vs ritonavir respectively, no significant differences.

Median increases in serum creatinine were 0.13 vs 0.09 mg/dL were greater in the cobicistat group (p< 0.001) most occurring by week 8 and stable thereafter, with 6 compared to 5 patients discontinuing for renal events. This was associated with a corresponding decrease in eGFR (-12.9 vs -9.1 mL/min respectively, p<0.001. In the cobicistat group, 1/6 was due to reduced eGFR, and 5/6 with laboratory markers associated with proximal tubopathy compared to 2/5 in the ritonavir group. These resolved on discontinuation.

Increases in total cholesterol (+5 vs +9 mg/dL, + = 0.081) and triglycerides (+19 vs +32 mg/dL, p=0.063) were numerically higher with ritonavir but not statistically different.

Cobicistat inhibits tubular secretion of creatine which reduces estimated but not actual GFR and has been reported in earlier studies.2

For clinical management, an increase of 0.4 mg/dL or greater may be able to be used as a conservative cut-off to address concerns about potential tenofovir renal tubular toxicity.3

Other ongoing formulations with cobicistat include:

  • elvitegravir/cobicistat/FTC/tenofovir alafenamide fumarate (TAF)
  • darunavir/cobicistat/FTC/TAF
  • atazanavir/cobicistat

Cobicistat was submitted to the FDA as a separate compound in June 2012 but has yet to receive FDA approval as a separate drug.


References

  1. Gallant JE et al. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results. J Infect Dis. (2013) doi: 10.1093/infdis/jit122. First published online: 26 March 2013.
  2. German P et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. JAIDS, Volume 60 - Issue 3 - p 219-220 (1 July 2012).
  3. Food and Drug Administration Center for Drug Evaluation and Research. Summary minutes of the Antiviral Drugs Advisory Committee Meeting, May 11, 2012.

Links to other websites are current at date of posting but not maintained.




This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.
 

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement